We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Powerful Tool Detects Fast-Spreading SARS-COV-2 Variants

By LabMedica International staff writers
Posted on 30 Jan 2025

Throughout the course of the COVID-19 pandemic, new variants of SARS-CoV-2 have emerged, each demonstrating increased transmissibility. More...

Viruses can mutate in ways that enhance their ability to infect hosts, either by increasing viral load or evading immune responses. Rapid detection of these mutations is crucial to understanding viral biology and identifying new variants that may require further investigation. Quickly identifying mutations that contribute to higher transmission rates can aid in outbreak control and help spot potential immune escape variants. However, determining how individual mutations influence viral transmission has proven to be a difficult task. To overcome this challenge, researchers have developed a tool capable of detecting SARS-CoV-2 variants with high transmission potential before they become widespread.

A team of scientists, led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute, Melbourne, Australia) and the University of Pittsburgh (Pittsburgh, PA, USA), analyzed millions of viral genome sequences from around the world. Their work revealed specific mutations that give SARS-CoV-2 a significant advantage in spreading. While many of these mutations were found in the virus’s spike protein, which is responsible for allowing the virus to enter human cells and is targeted by antibodies, the researchers also discovered important mutations in less-studied regions of the virus.

These mutations play a role in enhancing the virus's ability to bind to human cells, evade immune responses, or alter protein structure. Unlike previous methods, this new model, highlighted in Nature Communications, uses genomic surveillance data to accurately identify the mutations driving the spread of certain variants, even when these mutations appear in only a small fraction of cases. While the model was developed specifically for SARS-CoV-2, the researchers believe it can be adapted to track the transmission of other pathogens, such as influenza.

“Our method is like a magnifying glass for viral evolution, helping public health systems spot and monitor highly transmissible variants before they become widespread,” said Associate Professor John Barton from the University of Pittsburgh, co-lead author of the study. “Not only can we track SARS-CoV-2 more effectively, but our method can also be adapted to study the evolution of other pathogens, helping us stay ahead of future outbreaks. It’s a powerful tool for global efforts to tackle emerging diseases.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Thyroid Test
Anti-Thyroid EIA Test
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.